Ryan Rountree

Company: Nurix Therapeutics

Job title: Sr. Director, Preclinical Pharmacology

Seminars:

Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease 4:30 pm

Uncover NX-5948, a highly potent, CNS penetrant, targeted protein degrader of BTK in Phase 1 clinical development for B cell malignancies Evaluate how daily oral administration of NX-5948 provides efficacy in multiple preclinical models of autoimmune disease Learn how NX-5948 preclinical data supports further exploration of NX-5948 to treat autoimmune diseasesRead more

day: Day One